Cardiac amyloidosis in patient undergoing TAVR, why we need to think about it.

[1]  C. Di Mario,et al.  Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. , 2020, Circulation. Heart failure.

[2]  C. Di Mario,et al.  Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. , 2020, The Canadian journal of cardiology.

[3]  A. Petrie,et al.  Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. , 2020, European heart journal.

[4]  G. Pontone,et al.  Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. , 2020, JACC. Cardiovascular imaging.

[5]  R. John,et al.  Use of Implantable Electronic Devices in Patients With Cardiac Amyloidosis. , 2019, The Canadian journal of cardiology.

[6]  F. Perfetto,et al.  A Man in His 80s With Hypertension, Left Ventricular Hypertrophy, and Enlarged Biceps. , 2019, JAMA cardiology.

[7]  C. Morbach,et al.  Amyloidosis in Heart Failure , 2019, Current Heart Failure Reports.

[8]  M. Fontana,et al.  Cardiac Amyloidosis: Updates in Imaging , 2019, Current Cardiology Reports.

[9]  L. Køber,et al.  Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes. , 2019, Journal of the American College of Cardiology.

[10]  Sanjiv J. Shah,et al.  Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. , 2019, Journal of the American College of Cardiology.

[11]  C. Rapezzi,et al.  Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis: Is it Just Amyloid Infiltration? , 2019, JACC. Cardiovascular imaging.

[12]  D. Phelan,et al.  Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. , 2018, Journal of the American College of Cardiology.

[13]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[14]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[15]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[16]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[17]  D. Dingli,et al.  Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[18]  D. Forman,et al.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis , 2017, Journal of Cardiovascular Magnetic Resonance.

[19]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[20]  R. Falk,et al.  Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis , 2017, JAMA.

[21]  P. Kellman,et al.  Magnetic Resonance in Transthyretin Cardiac Amyloidosis. , 2017, Journal of the American College of Cardiology.

[22]  P. Elliott,et al.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.

[23]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[24]  J. Moon,et al.  Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic StenosisCLINICAL PERSPECTIVE , 2016 .

[25]  W. Jaber,et al.  Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis. , 2016, JACC. Cardiovascular imaging.

[26]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[27]  C. Rapezzi,et al.  Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. , 2016, JACC. Cardiovascular imaging.

[28]  J. Dubois-Randé,et al.  Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? , 2016, European heart journal.

[29]  C. Rapezzi,et al.  Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy , 2016, Open Heart.

[30]  P. Kellman,et al.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2015, Circulation.

[31]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[32]  G. Gensini,et al.  Echocardiographic and Biohumoral Characteristics in Patients With AL and TTR Amyloidosis at Diagnosis , 2015, Clinical cardiology.

[33]  H. Jono,et al.  Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis , 2015, Modern Pathology.

[34]  G. Gensini,et al.  Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[35]  W. Edwards,et al.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.

[36]  G. Merlini,et al.  Prognostic value of fragmented QRS in cardiac AL amyloidosis. , 2013, International journal of cardiology.

[37]  G. Merlini,et al.  Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis , 2013, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[38]  L. Padeletti,et al.  Right ventricular function in AL amyloidosis: characteristics and prognostic implication. , 2012, European heart journal cardiovascular Imaging.

[39]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Padeletti,et al.  Cardiac amyloidosis: the heart of the matter , 2013, Internal and Emergency Medicine.

[41]  J. Koziol,et al.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. , 2010, American heart journal.

[42]  F. Salvi,et al.  Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.

[43]  A. Singleton,et al.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study , 2008, Annals of medicine.

[44]  T. Mizutani,et al.  Trigger finger as an initial manifestation of familial amyloid polyneuropathy in a patient with Ile107Val TTR. , 2007, Internal medicine.

[45]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N. Athanasou,et al.  Localized Amyloid Deposition in Trigger Finger , 2001, Journal of hand surgery.

[47]  J. Reveille,et al.  Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population. , 1991, American journal of human genetics.

[48]  R A Kyle,et al.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.